자폐 스펙트럼 장애 치료제 시장(2026-2030년)

The global autism spectrum disorder therapeutics market is forecasted to grow by USD 935.5 mn during 2025-2030, accelerating at a CAGR of 7.3% during the forecast period. The report on the global autism spectrum disorder therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by development of early diagnostic programs and awareness initiatives, expansion of pipeline innovation and collaborative research frameworks, industrialization of targeted pharmacological interventions for genetic subsets.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global autism spectrum disorder therapeutics market is segmented as below:

By Distribution Channel

• Retail pharmacy
• Hospital pharmacy
• Online pharmacy

By Type

• Stimulants
• Selective serotonin reuptake inhibitors
• Antipsychotic drugs
• Sleep medications
• Others

By Application

• Autistic disorder
• Asperger syndrome
• Pervasive developmental disorder
• Others

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the integrated of precision medicine and biomarker-driven subtyping as one of the prime reasons driving the global autism spectrum disorder therapeutics market growth during the next few years. Also, growth of hybrid behavioral-pharmacologic and digital therapeutic platforms and expansion of cannabinoid research and novel neuro-modulators will lead to sizable demand in the market.

The report on the global autism spectrum disorder therapeutics market covers the following areas:

• Global autism spectrum disorder therapeutics market sizing
• Global autism spectrum disorder therapeutics market forecast
• Global autism spectrum disorder therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global autism spectrum disorder therapeutics market vendors that include AutismSTEP, Bristol Myers Squibb Co., CureMark LLC, F. Hoffmann La Roche Ltd., Jazz Pharmaceuticals Plc, Johnson and Johnson Services, Les Laboratoires Servier, Neurim Pharmaceuticals Ltd., Novartis AG, Oryzon Genomics SA, Otsuka Pharmaceutical Co Ltd., Scioto Biosciences Inc., Stalicla SA, Travere Therapeutics Inc., Yamo Pharmaceuticals LLC, Zynerba Pharmaceuticals Inc.. Also, the global autism spectrum disorder therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Autism Spectrum Disorder Therapeutics Market 2020 - 2024
  • Historic Market Size - Data Table on Global Autism Spectrum Disorder Therapeutics Market 2020 - 2024 ($ million)
• 5.2 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
• 5.3 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.4 Application segment analysis 2020 - 2024
  • Historic Market Size - Application Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI in global autism spectrum disorder therapeutics market
• 6.2 Impact of geopolitical conflict for global autism spectrum disorder therapeutics market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Distribution Channel

• 8.1 Market segments
• 8.2 Comparison by Distribution Channel
• 8.3 Retail pharmacy - Market size and forecast 2025-2030
• 8.4 Hospital pharmacy - Market size and forecast 2025-2030
• 8.5 Online pharmacy - Market size and forecast 2025-2030
• 8.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)

9 Market Segmentation by Type

• 9.1 Market segments
• 9.2 Comparison by Type
• 9.3 Stimulants - Market size and forecast 2025-2030
• 9.4 Selective serotonin reuptake inhibitors - Market size and forecast 2025-2030
• 9.5 Antipsychotic drugs - Market size and forecast 2025-2030
• 9.6 Sleep medications - Market size and forecast 2025-2030
• 9.7 Others - Market size and forecast 2025-2030
• 9.8 Market opportunity by Type
  • Market opportunity by Type ($ million)

10 Market Segmentation by Application

• 10.1 Market segments
• 10.2 Comparison by Application
• 10.3 Autistic disorder - Market size and forecast 2025-2030
• 10.4 Asperger syndrome - Market size and forecast 2025-2030
• 10.5 Pervasive developmental disorder - Market size and forecast 2025-2030
• 10.6 Others - Market size and forecast 2025-2030
• 10.7 Market opportunity by Application
  • Market opportunity by Application ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 Japan - Market size and forecast 2025-2030
  • 12.5.2 China - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Turkey - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 South Africa - Market size and forecast 2025-2030
  • 12.6.7 Colombia - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Development of early diagnostic programs and awareness initiatives
  • Expansion of pipeline innovation and collaborative research frameworks
  • Industrialization of targeted pharmacological interventions for genetic subsets
• 13.2 Market challenges
  • Intensification of clinical heterogeneity and patient stratification difficulties
  • Economic burden of high therapy costs and reimbursement volatility
  • Escalation of regulatory rigor and pediatric extrapolation hurdles
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Integrated of precision medicine and biomarker-driven subtyping
  • Growth of hybrid behavioral-pharmacologic and digital therapeutic platforms
  • Expansion of cannabinoid research and novel neuro-modulators

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 AutismSTEP
  • AutismSTEP - Overview
  • AutismSTEP - Product / Service
  • AutismSTEP - Key offerings
  • SWOT
• 15.5 Bristol Myers Squibb Co.
  • Bristol Myers Squibb Co. - Overview
  • Bristol Myers Squibb Co. - Product / Service
  • Bristol Myers Squibb Co. - Key news
  • Bristol Myers Squibb Co. - Key offerings
  • SWOT
• 15.6 CureMark LLC
  • CureMark LLC - Overview
  • CureMark LLC - Product / Service
  • CureMark LLC - Key offerings
  • SWOT
• 15.7 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.8 Jazz Pharmaceuticals Plc
  • Jazz Pharmaceuticals Plc - Overview
  • Jazz Pharmaceuticals Plc - Product / Service
  • Jazz Pharmaceuticals Plc - Key news
  • Jazz Pharmaceuticals Plc - Key offerings
  • SWOT
• 15.9 Johnson and Johnson Services
  • Johnson and Johnson Services - Overview
  • Johnson and Johnson Services - Business segments
  • Johnson and Johnson Services - Key news
  • Johnson and Johnson Services - Key offerings
  • Johnson and Johnson Services - Segment focus
  • SWOT
• 15.10 Les Laboratoires Servier
  • Les Laboratoires Servier - Overview
  • Les Laboratoires Servier - Product / Service
  • Les Laboratoires Servier - Key offerings
  • SWOT
• 15.11 Neurim Pharmaceuticals Ltd.
  • Neurim Pharmaceuticals Ltd. - Overview
  • Neurim Pharmaceuticals Ltd. - Product / Service
  • Neurim Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 15.12 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.13 Otsuka Pharmaceutical Co Ltd.
  • Otsuka Pharmaceutical Co Ltd. - Overview
  • Otsuka Pharmaceutical Co Ltd. - Product / Service
  • Otsuka Pharmaceutical Co Ltd. - Key offerings
  • SWOT
• 15.14 Scioto Biosciences Inc.
  • Scioto Biosciences Inc. - Overview
  • Scioto Biosciences Inc. - Product / Service
  • Scioto Biosciences Inc. - Key offerings
  • SWOT
• 15.15 Stalicla SA
  • Stalicla SA - Overview
  • Stalicla SA - Product / Service
  • Stalicla SA - Key offerings
  • SWOT
• 15.16 Travere Therapeutics Inc.
  • Travere Therapeutics Inc. - Overview
  • Travere Therapeutics Inc. - Product / Service
  • Travere Therapeutics Inc. - Key offerings
  • SWOT
• 15.17 Yamo Pharmaceuticals LLC
  • Yamo Pharmaceuticals LLC - Overview
  • Yamo Pharmaceuticals LLC - Product / Service
  • Yamo Pharmaceuticals LLC - Key offerings
  • SWOT
• 15.18 Zynerba Pharmaceuticals Inc.
  • Zynerba Pharmaceuticals Inc. - Overview
  • Zynerba Pharmaceuticals Inc. - Product / Service
  • Zynerba Pharmaceuticals Inc. - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations